{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:26:19Z","timestamp":1792459579460,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.yebeh.2021.107832","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T16:42:19Z","timestamp":1613925739000},"page":"107832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-7805","authenticated-orcid":false,"given":"Brad K.","family":"Kamitaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos D.","family":"Minacapelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1333-0925","authenticated-orcid":false,"given":"Christopher","family":"Wachuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0872-7867","authenticated-orcid":false,"given":"Kapil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Rustgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.107832_b0005","unstructured":"Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol. 2019 Apr;18:357-375."},{"key":"10.1016\/j.yebeh.2021.107832_b0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-2008-1073117","article-title":"Acute liver failure due to drugs","volume":"28","author":"Fontana","year":"2008","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.yebeh.2021.107832_b0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cld.2016.08.007","article-title":"Drug-induced liver disease: clinical course","volume":"21","author":"Saithanyamurthi","year":"2017","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.yebeh.2021.107832_b0020","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/lt.20204","article-title":"Liver transplantation for acute liver failure from drug induced liver injury in the United States","volume":"10","author":"Russo","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.yebeh.2021.107832_b0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","article-title":"New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?","volume":"2","author":"French","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.yebeh.2021.107832_b0030","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second-generation antiseizure medications: impact and future perspectives","volume":"19","author":"Perucca","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107832_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.26","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"Banda","year":"2016","journal-title":"Sci Data"},{"key":"10.1016\/j.yebeh.2021.107832_b0040","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40264-013-0116-9","article-title":"Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA adverse event reporting system (FAERS) database","volume":"36","author":"Brinker","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2021.107832_b0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.seizure.2005.12.009","article-title":"Antiepileptic drugs and liver disease","volume":"15","author":"Ahmed","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107832_b0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","article-title":"Drug development for refractory epilepsy: The past 25 years and beyond","volume":"44","author":"Golyala","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107832_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081208","article-title":"Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe","volume":"8","author":"Raschi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.yebeh.2021.107832_b0060","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pds.1746","article-title":"Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)","volume":"18","author":"Poluzzi","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2021.107832_b0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40801-018-0134-0","article-title":"Spontaneous reporting on adverse events by consumers in the United States: an analysis of the food and drug administration adverse event reporting system database","volume":"5","author":"Toki","year":"2018","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.yebeh.2021.107832_b0070","doi-asserted-by":"crossref","unstructured":"Rogers JR, Sarpatwari A, Desai RJ, Bohn JM, Khan NF, Kesselheim AS, et al. Effect of lawyer-submitted reports on signals of disproportional reporting in the Food and Drug Administration\u2019s adverse event reporting system, Drug Saf. 2019;42:85-93.","DOI":"10.1007\/s40264-018-0703-x"},{"key":"10.1016\/j.yebeh.2021.107832_b0075","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrd.2018.126","article-title":"Regulatory watch: FDA new drug approvals in Q2 2018","volume":"17","author":"Urquhart","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.yebeh.2021.107832_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2021.107832_b0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2008.01009.x","article-title":"Hepatotoxicity associated with antiepileptic drugs","volume":"118","author":"Bj\u00f6rnsson","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107832_b0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cld.2013.07.011","article-title":"Drug-induced liver injury from antiepileptic drugs","volume":"17","author":"Au","year":"2013","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.yebeh.2021.107832_b0095","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"key":"10.1016\/j.yebeh.2021.107832_b0100","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/epi.14591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System","volume":"59","author":"Borrelli","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107832_b0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1515\/dmdi-2013-0006","article-title":"Asymptomatic elevation of liver enzymes due to levetiracetam: a case report","volume":"28","author":"Sethi","year":"2013","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1016\/j.yebeh.2021.107832_b0110","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omx067","article-title":"Levetiracetam-induced transaminitis in a young male with traumatic brain injury","volume":"2017","author":"Rachamallu","year":"2017","journal-title":"Oxford Medical Case Reports"},{"key":"10.1016\/j.yebeh.2021.107832_b0115","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1212\/01.wnl.0000324604.11657.c6","article-title":"Levetiracetam as a possible cause of fulminant liver failure","volume":"71","author":"Tan","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107832_b0120","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s00415-015-8011-1","article-title":"Levetiracetam associated acute hepatic failure requiring liver transplantation: case report","volume":"263","author":"Selvaraj","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2021.107832_b0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcph.1313","article-title":"A comprehensive overview of the clinical pharmacokinetics of clobazam","volume":"59","author":"Tolbert","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107832_b0130","unstructured":"Lundbeck. Onfi (clobazam) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/202067s002,203993s002lbl.pdf. Revised November 2013. Accessed July 29, 2020."},{"key":"10.1016\/j.yebeh.2021.107832_b0135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMc1708349","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"377","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107832_b0140","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107832_b0145","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107832_b0150","unstructured":"Reporting and learning systems for medication errors: the role of pharmacovigilance centres: World Health Organizationh; 2014."},{"key":"10.1016\/j.yebeh.2021.107832_b0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cld.2009.02.001","article-title":"The asymptomatic outpatient with abnormal liver function tests","volume":"13","author":"Krier","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.yebeh.2021.107832_b0160","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12911-019-0999-1","article-title":"Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.yebeh.2021.107832_b0165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1684\/epd.2020.1191","article-title":"Testing blood and CSF in people with epilepsy: a practical guide","volume":"22","author":"Sutton","year":"2020","journal-title":"Epileptic Disord"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:35:46Z","timestamp":1761503746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":33,"alternative-id":["S1525505021000664"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107832","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107832"}}